Transcriptional suppression of BACH2 by the Bcr-Abl oncoprotein is mediated by PAX5

Leukemia

Volumn 27, Issue 2, 2013, Pages 409-415

  Casolari, D A ^a   Makri, M ^b   Yoshida, C ^b   Muto, A ^c   Igarashi, K ^c   Melo, J V ^a,b  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; GENOMIC DNA; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR BACH2; TRANSCRIPTION FACTOR PAX5; UNCLASSIFIED DRUG;

ARTICLE; BACH2 GENE; BINDING SITE; CHRONIC MYELOID LEUKEMIA; DOWN REGULATION; EXON; GEL MOBILITY SHIFT ASSAY; GENE; GENE CONSTRUCT; GENE DELETION; GENE EXPRESSION; GENE FUSION; GENE REPRESSION; HISTONE ACETYLATION; HISTONE METHYLATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; REGULATORY SEQUENCE; TRANSCRIPTION INITIATION SITE; TRANSIENT TRANSFECTION;

ACETYLATION; B-CELL-SPECIFIC ACTIVATOR PROTEIN; BASIC-LEUCINE ZIPPER TRANSCRIPTION FACTORS; BLAST CRISIS; CHROMATIN IMMUNOPRECIPITATION; DNA METHYLATION; ELECTROPHORETIC MOBILITY SHIFT ASSAY; FUSION PROTEINS, BCR-ABL; HISTONES; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; LUCIFERASES; TUMOR CELLS, CULTURED;

EID: 84873571369     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2012.220     Document Type: Article

References (49)

1. Deininger MW, Goldman JM, Melo JV. The molecular biology of chronic myeloid leukemia. Blood 2000; 96: 3343-3356.
2. Cortes J, Kantarjian HM, Giralt S, Talpaz M. Natural history and staging of chronic myelogenous leukaemia. Baillieres Clin Haematol 1997; 10: 277-290.
3. Bacher U, Haferlach T, Hiddemann W, Schnittger S, Kern W, Schoch C. Additional clonal abnormalities in Philadelphia-positive ALL and CML demonstrate a different cytogenetic pattern at diagnosis and follow different pathways at progression. Cancer Genet Cytogenet 2005; 157: 53-61.
4. Wong S, Witte ON. The BCR-ABL story: bench to bedside and back. Annu Rev Immunol 2004; 22: 247-306.
5. Barnes DJ, Melo JV. Cytogenetic and molecular genetic aspects of chronic myeloid leukaemia. Acta Haematol 2002; 108: 180-202.
6. Canitrot Y, Falinski R, Louat T, Laurent G, Cazaux C, Hoffmann JS et al. p210 BCR/ABL kinase regulates nucleotide excision repair (NER) and resistance to ultraviolet (UV) radiation. Blood 2003; 102: 2632-2637.
7. Nowicki MO, Falinski R, Koptyra M, Slupianek A, Stoklosa T, Gloc E et al. BCR/ABL oncogenic kinase promotes unfaithful repair of the reactive oxygen speciesdependent DNA double-strand breaks. Blood 2004; 104: 3746-3753.
8. Deininger MW, Vieira S, Mendiola R, Schultheis B, Goldman JM, Melo JV. BCR-ABL tyrosine kinase activity regulates the expression of multiple genes implicated in the pathogenesis of chronic myeloid leukemia. Cancer Res 2000; 60: 2049-2055.
9. Deininger MW, Vieira SA, Parada Y, Banerji L, Lam EW, Peters G et al. Direct relation between BCR-ABL tyrosine kinase activity and cyclin D2 expression in lymphoblasts. Cancer Res 2001; 61: 8005-8013.
10. Vieira SA, Deininger MW, Sorour A, Sinclair P, Foroni L, Goldman JM et al. Transcription factor BACH2 is transcriptionally regulated by the BCR/ABL oncogene. Genes Chromosomes Cancer 2001; 32: 353-363.
11. Oyake T, Itoh K, Motohashi H, Hayashi N, Hoshino H, Nishizawa M et al. Bach proteins belong to a novel family of BTB-basic leucine zipper transcription factors that interact with MafK and regulate transcription through the NF-E2 site. Mol Cell Biol 1996; 16: 6083-6095.
12. Muto A, Hoshino H, Madisen L, Yanai N, Obinata M, Karasuyama H et al. Identification of Bach2 as a B-cell-specific partner for small maf proteins that negatively regulate the immunoglobulin heavy chain gene 3' enhancer. EMBO J 1998; 17: 5734-5743.
13. Muto A, Tashiro S, Tsuchiya H, Kume A, Kanno M, Ito E et al. Activation of Maf/AP-1 repressor Bach2 by oxidative stress promotes apoptosis and its interaction with promyelocytic leukemia nuclear bodies. J Biol Chem 2002; 277: 20724-20733.
14. Muto A, Tashiro S, Nakajima O, Hoshino H, Takahashi S, Sakoda E et al. The transcriptional programme of antibody class switching involves the repressor Bach2. Nature 2004; 429: 566-571.
15. Yoshida C, Yoshida F, Sears DE, Hart SM, Ikebe D, Muto A et al. Bcr-Abl signaling through the PI-3/S6 kinase pathway inhibits nuclear translocation of the transcription factor Bach2, which represses the antiapoptotic factor heme oxygenase-1. Blood 2007; 109: 1211-1219.
16. Cobaleda C, Schebesta A, Delogu A, Busslinger M. Pax5: the guardian of B cell identity and function. Nat Immunol 2007; 8: 463-470.
17. Wakatsuki Y, Neurath MF, Max EE, Strober W. The B cell-specific transcription factor BSAP regulates B cell proliferation. J Exp Med 1994; 179: 1099-1108.
18. Qiu G, Stavnezer J. Overexpression of BSAP/Pax-5 inhibits switching to IgA and enhances switching to IgE in the I.29 mu B cell line. J Immunol 1998; 161: 2906-2918.
19. Usui T, Wakatsuki Y, Matsunaga Y, Kaneko S, Koseki H, Kita T. Overexpression of B cell-specific activator protein (BSAP/Pax-5) in a late B cell is sufficient to suppress differentiation to an Ig high producer cell with plasma cell phenotype. J Immunol 1997; 158: 3197-3204.
20. Fernandez DM, Essafi A, Soeiro I, Pietersen AM, Birkenkamp KU, Edwards CS et al. FoxO3a and BCR-ABL regulate cyclin D2 transcription through a STAT5/BCL6-dependent mechanism. Mol Cell Biol 2004; 24: 10058-10071.
21. Rance JB, Follows GA, Cockerill PN, Bonifer C, Lane DA, Simmonds RE. Regulation of the human endothelial cell protein C receptor gene promoter by multiple Sp1 binding sites. Blood 2003; 101: 4393-4401.
22. Sato H, Wang D, Kudo A. Dissociation of Pax-5 from KI and KII sites during kappachain gene rearrangement correlates with its association with the underphosphorylated form of retinoblastoma. J Immunol 2001; 166: 6704-6710.
23. Sawado T, Igarashi K, Groudine M. Activation of beta-major globin gene transcription is associated with recruitment of NF-E2 to the beta-globin LCR and gene promoter. Proc Natl Acad Sci USA 2001; 98: 10226-10231.
24. Strahl BD, Allis CD. The language of covalent histone modifications. Nature 2000; 403: 41-45.
25. Schebesta A, McManus S, Salvagiotto G, Delogu A, Busslinger GA, Busslinger M. Transcription factor Pax5 activates the chromatin of key genes involved in B cell signaling, adhesion, migration, and immune function. Immunity 2007; 27: 49-63.
26. Essafi A, Fernandez dM, Hassen YA, Soeiro I, Mufti GJ, Thomas NS et al. Direct transcriptional regulation of Bim by FoxO3a mediates STI571-induced apoptosis in Bcr-Abl-expressing cells. Oncogene 2005; 24: 2317-2329.
27. Kuroda J, Puthalakath H, Cragg MS, Kelly PN, Bouillet P, Huang DC et al. Bim and Bad mediate imatinib-induced killing of Bcr/Abl\+ leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic. Proc Natl Acad Sci USA 2006; 103: 14907-14912.
28. Perrotti D, Calabretta B. Post-transcriptional mechanisms in BCR/ABL leukemogenesis: role of shuttling RNA-binding proteins. Oncogene 2002; 21: 8577-8583.
29. Perrotti D, Calabretta B. Translational regulation by the p210 BCR/ABL oncoprotein. Oncogene 2004; 23: 3222-3229.
30. Iervolino A, Santilli G, Trotta R, Guerzoni C, Cesi V, Bergamaschi A et al. hnRNP A1 nucleocytoplasmic shuttling activity is required for normal myelopoiesis and BCR/ABL leukemogenesis. Mol Cell Biol 2002; 22: 2255-2266.
31. Perrotti D, Cesi V, Trotta R, Guerzoni C, Santilli G, Campbell K et al. BCR-ABL suppresses C/EBPalpha expression through inhibitory action of hnRNP E2. Nat Genet 2002; 30: 48-58.
32. Rahman M, Hirabayashi Y, Ishii T, Kodera T, Watanabe M, Takasawa N et al. A repressor element in the 5'-untranslated region of human Pax5 exon 1A. Gene 2001; 263: 59-66.
33. McManus S, Ebert A, Salvagiotto G, Medvedovic J, Sun Q, Tamir I et al. The transcription factor Pax5 regulates its target genes by recruiting chromatinmodifying proteins in committed B cells. EMBO J 2011; 30: 2388-2404.
34. Hamada T, Yonetani N, Ueda C, Maesako Y, Akasaka H, Akasaka T et al. Expression of the PAX5/BSAP transcription factor in haematological tumour cells and further molecular characterization of the t(9;14)(p13;q32) translocation in B-cell non-Hodgkin's lymphoma. Br J Haematol 1998; 102: 691-700.
35. Stuart ET, Kioussi C, Aguzzi A, Gruss P. PAX5 expression correlates with increasing malignancy in human astrocytomas. Clin Cancer Res 1995; 1: 207-214.
36. Li X, Cheung KF, Ma X, Tian L, Zhao J, Go MY et al. Epigenetic inactivation of paired box gene 5, a novel tumor suppressor gene, through direct upregulation of p53 is associated with prognosis in gastric cancer patients. Oncogene 2012; 31: 3419-3430.
37. Iacobucci I, Lonetti A, Paoloni F, Papayannidis C, Ferrari A, Storlazzi CT et al. The PAX5 gene is frequently rearranged in BCR-ABL1-positive acute lymphoblastic leukemia but is not associated with outcome. A report on behalf of the GIMEMA Acute Leukemia Working Party. Haematologica 2010; 95: 1683-1690.
38. Mullighan CG, Goorha S, Radtke I, Miller CB, Coustan-Smith E, Dalton JD et al. Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature 2007; 446: 758-764.
39. Kawamata N, Pennella MA, Woo JL, Berk AJ, Koeffler HP. Dominant-negative mechanism of leukemogenic PAX5 fusions. Oncogene 2012; 31: 966-977.
40. An Q, Wright SL, Konn ZJ, Matheson E, Minto L, Moorman AV et al. Variable breakpoints target PAX5 in patients with dicentric chromosomes: a model for the basis of unbalanced translocations in cancer. Proc Natl Acad Sci USA 2008; 105: 17050-17054.
41. Ross ME, Zhou X, Song G, Shurtleff SA, Girtman K, Williams WK et al. Classification of pediatric acute lymphoblastic leukemia by gene expression profiling. Blood 2003; 102: 2951-2959.
42. Bhojwani D, Kang H, Menezes RX, Yang W, Sather H, Moskowitz NP et al. Gene expression signatures predictive of early response and outcome in high-risk childhood acute lymphoblastic leukemia: A Children's Oncology Group Study [corrected]. J Clin Oncol 2008; 26: 4376-4384.
43. Klemm L, Duy C, Iacobucci I, Kuchen S, von Levetzow G, Feldhahn N et al. The B cell mutator AID promotes B lymphoid blast crisis and drug resistance in chronic myeloid leukemia. Cancer Cell 2009; 16: 232-245.
44. Zhang X, Lin Z, Kim I. Pax5 expression in non-Hodgkin's lymphomas and acute leukemias. J Korean Med Sci 2003; 18: 804-808.
45. Scherle PA, Dorshkind K, Witte ON. Clonal lymphoid progenitor cell lines expressing the BCR/ABL oncogene retain full differentiative function. Proc Natl Acad Sci USA 1990; 87: 1908-1912.
46. Neurath MF, Strober W, Wakatsuki Y. The murine Ig 3' alpha enhancer is a target site with repressor function for the B cell lineage-specific transcription factor BSAP (NF-HB, S alpha-BP). J Immunol 1994; 153: 730-742.
47. Griesser H, Tkachuk D, Reis MD, Mak TW. Gene rearrangements and translocations in lymphoproliferative diseases. Blood 1989; 73: 1402-1415.
48. Poppe B, De Paepe P, Michaux L, Dastugue N, Bastard C, Herens C et al. PAX5/IGH rearrangement is a recurrent finding in a subset of aggressive B-NHL with complex chromosomal rearrangements. Genes Chromosomes Cancer 2005; 44: 218-223.
49. Kamio T, Toki T, Kanezaki R, Sasaki S, Tandai S, Terui K et al. The B cell-specific transcription factor BACH2 modifies the cytotoxic effects of anticancer drugs. Blood 2003; 102: 3317-3322.